Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 1.00 |
| ▸ | MTOR | P42345 | 14/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.59 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.55 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3133403 | 0.86 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL3991523 | 0.83 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CGLRRK2 | |
| SCHEMBL22287937 | 0.74 | PIK3CA (0.75) | PIK3CAMTORPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL3431626 | 0.74 | PIK3CA (0.59) | PIK3CAMTORPIK3CDPIK3CGLRRK2 | |
| SCHEMBL4278372 | 0.74 | PIK3CA (0.59) | PIK3CAMTORPIK3CDPIK3CGLRRK2 | |
| SCHEMBL5593037 | 0.74 | PIK3CA (0.66) | PIK3CAMTORPIK3CDPIK3CGLRRK2 | |
| SCHEMBL16912833 | 0.74 | PIK3CA (0.73) | PIK3CAMTORPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL2902888 | 0.74 | MTOR (0.67) | PIK3CAMTORPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL3993229 | 0.74 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL3991904 | 0.73 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CGLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100003250-A1 | (2-ARYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)MORPHOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-07 | — | — | US | claimed |
| WO-2010002954-A1 | (2-ARYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)MORPHOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-07 | — | — | WO | claimed |
| US-20100003250-A1 | (2-ARYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)MORPHOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2010002954-A1 | (2-ARYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)MORPHOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003250-A1 | (2-ARYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)MORPHOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, RICTOR, MAPKAP1 | PIK3CA 4/4885MTOR 1/4885PIK3CD 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.